Six decades of cellular senescence: from Hayflick's limit to a therapeutic target
An abstract review traces how cellular senescence moved from a described limit on cultured cell division to a stress response, a driver of chronic pathology and a clinically actionable process. [1]
Automatic summary · not editorially reviewed
The key findings
Hayflick and Moorhead described the finite proliferative lifespan of cultured human cells in 1961. [1]
The SASP revealed that senescent cells actively communicate with and remodel their tissue environment. [1]
Genetic mouse models demonstrated causal roles for senescent cells in tissue repair, aging and age-related disease. [1]
The source at a glance
- Study type / format
- Abstract of a review article
- Population / context
- Cultured human cells, genetic mouse models and the research field of cellular senescence as described in the abstract
- Summary based on
- Study abstract
- Original publication
- October 2, 2026
From Hayflick's cultured-cell limit to a stress response
The abstract says senescence was discovered in 1961, when Hayflick and Moorhead described the finite proliferative lifespan of cultured human cells. It was first viewed as a consequence of cellular aging. Later work identified telomere shortening, senescence biomarkers, and oncogene- and damage-induced senescence. This established the molecular basis and a role as a tumor-suppressive stress response.
Supporting source [1]
SASP and mouse models: environment and causal roles
The discovery of the senescence-associated secretory phenotype (SASP) changed the field, the abstract states, by showing that senescent cells actively communicate with and remodel their tissue environment. Genetic mouse models later showed causal roles for senescent cells in tissue repair, aging and age-related disease. Senotherapeutics then established senescence as a therapeutic target.
Supporting source [1]
Conceptual transitions and emerging tools in the review
The review traces transitions from replicative endpoint to stress-response program, regulator of tissue homeostasis, driver of chronic pathology and clinically actionable process. It discusses the discoveries, controversies and technological advances behind these transitions. It also asks how single-cell technologies, precision biomarkers and targeted interventions are shaping the next era of senescence research.
Supporting source [1]
How to interpret this
This explainer is based only on the abstract; the full text was not reviewed. The abstract names no study design, sample, follow-up or effect sizes, and its historical and preclinical points do not establish human lifespan benefits.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Klaver M, Steeneken LS, Veeningen N, Altulea A, Demaria M. · europepmc.org · October 2, 2026